CD274 and metastatic melanoma: The presence of PD-L1 in tumor tissues has been found to correlate with a better clinical response to immunotherapy drugs targeting the PD-1/PD-L1 axis and better prognosis for certain cancers including metastatic melanoma, non-small cell lung cancer, and metastatic triple-negative breast cancer (31, 32).